Print

Five Takeaways from the Second Circuit's Namenda Decision

Read the full article (PDF) >

The Second Circuit's recent decision in New York v. Actavis, a case concerning the Alzheimer’s Disease treatment Namenda, grabbed headlines as the first appellate decision to uphold an injunction barring a branded pharmaceutical manufacturer from pulling a patented drug from the market. Now that the dust has settled after the ruling, it is time to assess how the decision could impact antitrust law inside and outside of the pharmaceutical industry.

COPYRIGHT © 2015 BY THE BUREAU OF NATIONAL AFFAIRS, INC. ISSN

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.